C. Ninalga

发表

Optimization of the MB49 mouse bladder cancer model for adenoviral gene therapy

T. Tötterman, P. Malmström, M. Alimohammadi, 2005, Laboratory animals.

Human bladder carcinoma is dominated by T-regulatory cells and Th1 inhibitory cytokines.

T. Tötterman, P. Malmström, M. de la Torre, 2007, The Journal of urology.

Dendritic cells engineered to express CD40L continuously produce IL12 and resist negative signals from Tr1/Th3 dominated tumors

T. Tötterman, A. Loskog, C. Ninalga, 2006, Cancer Immunology, Immunotherapy.

Adenovirus CD40 Ligand Gene Therapy Counteracts Immune Escape Mechanisms in the Tumor Microenvironment1

M. Essand, O. Korsgren, S. Vikman, 2004, The Journal of Immunology.

Counteracts Immune Escape Mechanisms in Adenovirus CD40 Ligand Gene Therapy

M. Essand, O. Korsgren, S. Vikman, 2004 .

Adenovirus CD 40 Ligand Gene Therapy Counteracts Immune Escape Mechanisms in the Tumor Microenvironment 1

M. Essand, O. Korsgren, S. Vikman, 2004 .

Cancer immunotherapy : a preclinical study of urinary bladder cancer.

C. Ninalga, 2006 .

CpG Therapy is Superior to BCG in an Orthotopic Bladder Cancer Model and Generates CD4+ T-cell Immunity

M. Essand, A. Loskog, C. Ninalga, 2008, Journal of immunotherapy.

CpG Oligonucleotide Therapy Cures Subcutaneous and Orthotopic Tumors and Evokes Protective Immunity in Murine Bladder Cancer

M. Essand, A. Loskog, C. Ninalga, 2005, Journal of immunotherapy.